Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)
Numerous patients were not treated with intensified therapies despite their increased effectiveness. First-line APA + ADT in mHSPC was associated with statistically significantly longer OS, longer TTCR, and faster and deeper PSA responses than other life-prolonging treatments in real-world clinical practice in the US.
Authors
- Suneel Mundle (ORCID: https://orcid.org/0000-0003-4867-172X)
- Benjamin Louis Maughan (ORCID: https://orcid.org/0000-0002-0010-8551)
- Lawrence I. Karsh (ORCID: https://orcid.org/0000-0002-3095-8303)
- X. Wang
- Mehregan Nematian‐Samani
- Yanfang Liu (ORCID: https://orcid.org/0000-0002-4091-7679)
Institutions
- University of Utah (US)
- Huntsman Cancer Institute (US)
- Denver Public Health (US)
- Johnson & Johnson (Germany) (DE)
- Janssen (Germany) (DE)
- Janssen (United States) (US)
Publication Details
- Journal
- Prostate Cancer and Prostatic Diseases
- Published
- 2024-12-19
- DOI
- https://doi.org/10.1038/s41391-024-00929-6
- Citations
- 9
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.77
Funders
- Janssen Biotech